Compare Gilead Sciences, Inc. (GILD) vs Cloudflare Inc (NET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Cloudflare Inc — how do they compare? Gilead Sciences, Inc. trades at $135.36 (market cap $163.51B), while Cloudflare Inc trades at $271.62 (market cap $96.91B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Cloudflare Inc pays none. Which is the better fit depends on your goals.
| GILD | NET | |
|---|---|---|
Market Cap | $163.51B | $96.91B |
Sector | Health | Technology |
52-Week High | $155.80 | $281.69 |
52-Week Low | $108.22 | $160.16 |
Enterprise Value | $178.05B | $96.27B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Cloudflare (NET) trades at $274.12, down 2.69% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. Revenue growth is robust, reaching $2.17B in 2025, though net margins remain negative at -4.72%. Recent news highlights AI integration in cybersecurity, with a research pilot with OpenAI announced on July 8, 2026, and a Q2 2026 earnings report scheduled for August 6, 2026.
The stock offers growth potential from AI-driven demand but carries valuation risks with a high P/S of 41.06 and negative profitability. Analyst consensus is strongly bullish with a $261 price target, yet competition and cash burn from investing activities pose challenges for sustained equity gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Cloudflare Inc
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →
